Sekisui XenoTech announced the appointment of Dr. Darren Warren, PhD, as the company’s new Chief Operating Officer. Warren has over 15 years of leadership experience with Contract Research Organizations (CROs) and almost 30 years of leadership experience in the pharmaceutical industry. October 16th marked his first day as COO at Sekisui XenoTech.
Warren is has expertise in operations, business, strategy, and science for service sector research organizations. His most recent position prior to Sekisui XenoTech was Vice President and General Manager with a west coast CRO, and his industry experience includes Ricerca Biosciences, SNBL USA, Charles River Labs and Bayer Corporation. Warren obtained his PhD in Pharmacology and Toxicology from the University of California, Davis in 1986.
Warren specializes in identifying and accelerating strategic and operational measures that strengthen performance with sustained multi-million dollar operational results.
“Dr. Warren’s demonstrated proficiency at combining expertise with methodical and pragmatic approaches to meet the challenges faced by today’s research industry, along with strong insights into emerging opportunities, trends, and issues, made him the clear choice for this position,” Dr. Toshinari Ohara, PhD, CEO of Sekisui XenoTech, said. “Darren is committed to the highest level of quality, professionalism and excellence, which is in perfect alignment with Sekisui XenoTech’s philosophy.”